Second-line hormonotherapy for breast cancer: Uselessness of first-line continuation

P. Pronzato, A. Rubagotti, D. Amoroso, G. Bertelli, P. Queirolo, M. R. Sertoli, M. Rosso, P. Gallotti, C. Monzeglio, R. Rosso

Research output: Contribution to journalArticlepeer-review

Abstract

The hypothesis that the results of second line hormonotherapy for breast cancer may be ameliorated with continuation of the first line has been explored in a randomized trial. Patients progressing under tamoxifen were randomly allocated to aminoglutethimide and hydrocortisone acetate with or without tamoxifen continuation. No difference has been observed between the two arms in terms of response rate and progression-free or overall survival.

Original languageEnglish
Pages (from-to)522-525
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume16
Issue number6
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Second-line hormonotherapy for breast cancer: Uselessness of first-line continuation'. Together they form a unique fingerprint.

Cite this